Bis(pyrene)-Doped Cationic Dipeptide Nanoparticles for Two-Photon-Activated Photodynamic Therapy

Sun, Bingbing; Wang, Lei; Li, Qi; He, Pingping; Liu, Huiling; Wang, Hao; Yang, Yang; Li, Junbai

doi:10.1021/acs.biomac.7b00780

Cited by 50 publications

(36 citation statements)

References 41 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential of 3D‐resolved two‐photon‐actuated nanomedicine has been exploited via various nanomaterials such as semiconductor and carbon nanodots, polymeric, organic, silicon, gold, graphene and graphene oxide, silica hybrid, and other inorganic nanomaterials. What are the advantages of silica‐based nanoparticles?…”

Section: Two‐photon‐sensitive Organosilica Nanomaterialsmentioning

confidence: 99%

Two‐Photon‐Excited Silica and Organosilica Nanoparticles for Spatiotemporal Cancer Treatment

Croissant

Zink

Raehm

et al. 2018

Adv Healthcare Materials

View full text Add to dashboard Cite

Coherent two-photon-excited (TPE) therapy in the near-infrared (NIR) provides safer cancer treatments than current therapies lacking spatial and temporal selectivities because it is characterized by a 3D spatial resolution of 1 µm and very low scattering. In this review, the principle of TPE and its significance in combination with organosilica nanoparticles (NPs) are introduced and then studies involving the design of pioneering TPE-NIR organosilica nanomaterials are discussed for bioimaging, drug delivery, and photodynamic therapy. Organosilica nanoparticles and their rich and well-established chemistry, tunable composition, porosity, size, and morphology provide ideal platforms for minimal side-effect therapies via TPE-NIR. Mesoporous silica and organosilica nanoparticles endowed with high surface areas can be functionalized to carry hydrophobic and biologically unstable two-photon absorbers for drug delivery and diagnosis. Currently, most light-actuated clinical therapeutic applications with NPs involve photodynamic therapy by singlet oxygen generation, but low photosensitizing efficiencies, tumor resistance, and lack of spatial resolution limit their applicability. On the contrary, higher photosensitizing yields, versatile therapies, and a unique spatial resolution are available with engineered two-photon-sensitive organosilica particles that selectively impact tumors while healthy tissues remain untouched. Patients suffering pathologies such as retinoblastoma, breast, and skin cancers will greatly benefit from TPE-NIR ultrasensitive diagnosis and therapy.

show abstract

Section: Two‐photon‐sensitive Organosilica Nanomaterialsmentioning

confidence: 99%

Two‐Photon‐Excited Silica and Organosilica Nanoparticles for Spatiotemporal Cancer Treatment

Croissant

Zink

Raehm

et al. 2018

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Due to the amphiphilic character, Ru‐PEG can self‐assemble into nanoparticles in H 2 O. BP may be readily encapsulated in Ru‐PEG nanoparticles through hydrophobic interaction as well as π−π interaction. [ 8 ]…”

Section: Resultsmentioning

confidence: 99%

“…In this regard, 1,3‐phenylenebis(pyren‐1‐ylmethanone) (abbreviate as BP, see Scheme for the structure) is a particular candidate by virtue of its extremely large δ 2 values (δmax = 2.8 × 10 5 GM) and a high emission quantum yield (Φ = 0.33 for the nanoaggregates in water). [ 8 ] The fluorescence of BP nanoaggregates covers a wide range from 450 to 650 nm, which encompasses the 1 MLCT absorption bands of most Ru(II) complexes very well. As a result, an efficient Förster resonance energy transfer (FRET) from the two‐photon excited BP to a Ru(II)‐based PACT agent may be expected, leading to NIR‐activated ligand dissociation and anticancer activity.…”

Section: Introductionmentioning

confidence: 99%

A Ru(II)‐Based Nanoassembly Exhibiting Theranostic PACT Activity in NIR Region

Wang

Tian

Sun

et al. 2020

Part & Part Syst Charact

View full text Add to dashboard Cite

upon irradiation, has attracted much attention in recent years. [2] Photoactivation may provide a spatial and temporal control on drug activity and thus reduce sideeffects significantly. Over the past decades, Pt(IV) complexes which can undergo photo reduction to form active Pt(II) species were developed and showed improved efficacy. [3] To address Pt(II) drug-based problems, Ru(II) complexes with anticancer activity were also explored intensively and extensively. [4] Of them, the Ru(II) complexes with PACT potentials are drawing increasing attention due to their expected higher selectivity against tumors. Unlike their Pt(IV) counterparts, Ru(II)-based PACT agents generally rely on ligand photosubstitution reactions, and the anticancer activity originates from either the resultant Ru(II) aqua complexes or the released photolabile ligands or both. [5] To realize clinical application, the currently developed PACT agents, including Ru(II)-based ones, are still faced with a great challenge, i.e., how to shift their photoactivation wavelengths to the phototherapeutic window of 650-900 nm to achieve deeper tissue penetration. The photoinduced ligand dissociation of Ru(II) complexes generally occurs through a triplet metal-centered ( 3 MC) state, which is thermally accessed from a low-lying triplet metal to ligand charge transfer ( 3 MLCT) state. [5] Further extension of the absorption of a Ru(II) complex often enlarges the energy gap between 3 MC and 3 MLCT states, consequently leads to a quite low quantum yield of ligand photodissociation. By innovative utilization of strained ligands to lower the 3 MC state energy, some elegant works successfully moved the excitation wavelengths to around 600 nm and maintained effective ligand photodissociation. [6] There is still a large room for further optimizing photoactivation to the ideal window. Besides, the examined Ru(II)-based PACT agents are almost non-emissive at room temperature, which limits their theranostic applications.Two-photon excitation is a powerful strategy to realize photoactivation in the near-infrared (NIR) region, [7] however, to the best of our knowledge has not been applied in Ru(II) based PACT agents yet. Due to the small two-photon absorption cross sections (δ 2 ) of common Ru(II) complexes (<300 Goeppert Mayer (GM), 1 GM = 10 −50 cm 4 s photon −1 ), [7] sensitization is Photoactivated chemotherapy (PACT) has appealing merits over traditional chemotherapy as well as photodynamic therapy (PDT) by virtue of its spatial and temporal control on drug activity and oxygen-independent mechanisms of action. However, the short photoactivation wavelengths, e.g., visible light-activated Ru(II)-based PACT agents, limit the clinical application severely. In this work, a facile construction of supramolecular nanoparticles from a poly(ethylene glycol) (PEG)-modified [Ru(dip) 2 (py-SO 3 )] + (abbreviated as Ru-PEG, dip = 4,7-diphenyl-1,10-phenanthroline, py-SO 3 = pyridine-2-sulfonate) and 1,3-phenylenebis(pyren-1-ylmethanone) (BP) is shown. While Ru-PEG may under...

show abstract

“…Such combined energy would be similar to the energy supplied by one short wavelength-photon for excitation of PSs ( Figure 7 ). One important factor that needs to be considered in TPA is the ability of PS to absorb two photons concurrently, which is quantified by the TPA cross-section (δ), expressed as Goeppert–Mayer units (GM) [ 123 , 124 , 125 ]. Table 2 shows the similarities and differences between traditional one-photon PDT and two-photon PDT.…”

Section: Future Perspective—how To Improve Anticancer Activity Of mentioning

confidence: 99%

Recent Emergence of Rhenium(I) Tricarbonyl Complexes as Photosensitisers for Cancer Therapy

Liew

Zulkefeli

et al. 2020

Molecules

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is emerging as a significant complementary or alternative approach for cancer treatment. PDT drugs act as photosensitisers, which upon using appropriate wavelength light and in the presence of molecular oxygen, can lead to cell death. Herein, we reviewed the general characteristics of the different generation of photosensitisers. We also outlined the emergence of rhenium (Re) and more specifically, Re(I) tricarbonyl complexes as a new generation of metal-based photosensitisers for photodynamic therapy that are of great interest in multidisciplinary research. The photophysical properties and structures of Re(I) complexes discussed in this review are summarised to determine basic features and similarities among the structures that are important for their phototoxic activity and future investigations. We further examined the in vitro and in vivo efficacies of the Re(I) complexes that have been synthesised for anticancer purposes. We also discussed Re(I) complexes in conjunction with the advancement of two-photon PDT, drug combination study, nanomedicine, and photothermal therapy to overcome the limitation of such complexes, which generally absorb short wavelengths.

show abstract

Bis(pyrene)-Doped Cationic Dipeptide Nanoparticles for Two-Photon-Activated Photodynamic Therapy

Cited by 50 publications

References 41 publications

Two‐Photon‐Excited Silica and Organosilica Nanoparticles for Spatiotemporal Cancer Treatment

Two‐Photon‐Excited Silica and Organosilica Nanoparticles for Spatiotemporal Cancer Treatment

A Ru(II)‐Based Nanoassembly Exhibiting Theranostic PACT Activity in NIR Region

Recent Emergence of Rhenium(I) Tricarbonyl Complexes as Photosensitisers for Cancer Therapy

Contact Info

Product

Resources

About